Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
68Ga-NODAGA-SNA009 in Patients With Colorectal Cancer
NCT07597759Phase 1Completed
- Sponsor
- SmartNuclide
- Start
- Oct 2025
- Primary completion
- Dec 2025
- Modality
- Nanobodies (VHH)
- Countries
- 1
01
Overview
Phase 1, open-label trial of 68Ga-NODAGA-SNA009 in colorectal cancer (CRC) (4 arms), sponsored by SmartNuclide. Primary endpoints: Safety and Tolerability at 1 week, Radiation Characters at 4 hours and 1 more. Started Oct 2025; status: completed.
02
Drugs
68Ga-NODAGA-SNA009
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT07597759.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07597759.